European approval for third biologic migraine therapy

19 November 2018
2019_biotech_test_vial_discovery_big

As expected, following a positive recommendation from its advisory panel in September, the European Medicines Agency has granted approval for Emgality (galcanezumab), in the treatment of migraines.

Eli Lilly (NYSE: LLY) says it has won approval to market the CGRP-inhibitor for the prophylaxis of migraine in adults who have at least four migraine days per month.

Emgality was approved in the USA in September, the third such migraine therapy to be approved, after Amgen’s (Nasdaq: AMGN) Aimovig (erenumab) and Teva Pharmaceutical’s (‎NYSE‎: TEVA) Ajovy (fremanezumab).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology